Distinguishing between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be challenging, especially when symptoms overlap. Both affect the gut and cause abdominal pain, bloating, and bowel habit changes. Yet they differ fundamentally in cause, mechanism, and treatment. One key difference lies in the gut microbiome, the trillions of bacteria and other microorganisms in the digestive tract, which plays a distinct role in each condition.
What is the gut microbiome?
The gut microbiome is the community of microorganisms, mainly bacteria, colonising the intestines. These organisms help digest food, produce vitamins, protect against pathogens, and communicate with the immune system. Composition varies between individuals and can be influenced by diet, medication, infection, and inflammation. When the balance shifts, a state called dysbiosis, it can contribute to or worsen gut symptoms and inflammation.
IBD vs IBS: a brief comparison
IBD, including Crohn’s disease and ulcerative colitis, is a chronic inflammatory condition driven by abnormal immune response that damages the gut lining. It is confirmed through endoscopy, biopsy, imaging, and blood markers. IBS is a functional gut disorder characterised by altered motility, heightened sensitivity, and disordered gut-brain communication. IBS causes no visible inflammation or tissue damage and is diagnosed based on symptoms after excluding other conditions.
Both involve abdominal discomfort, diarrhoea, and urgency, but the underlying biology and microbiome differ markedly.
How the microbiome differs in IBD
In IBD, the microbiome shows consistent, often dramatic changes reflecting ongoing immune activation and tissue damage.
Reduced microbial diversity
People with IBD typically have fewer bacterial types than healthy individuals. This reduction is most pronounced during active inflammation and often persists during remission. Diverse microbiomes are generally more stable and better at protective functions, such as producing short-chain fatty acids that fuel gut cells and regulate immune responses.
Loss of beneficial bacteria
Several bacteria supporting gut health are depleted in IBD. Faecalibacterium prausnitzii, a major butyrate producer with anti-inflammatory properties, is consistently reduced in Crohn’s disease and ulcerative colitis. Other beneficial groups, including Roseburia and Eubacterium families, are also diminished. These losses weaken the gut’s ability to regulate inflammation and maintain intestinal barrier integrity.
Increase in potentially harmful bacteria
Simultaneously, certain inflammation-associated bacteria become more abundant. Escherichia coli strains, particularly those that adhere to and invade gut cells, are more common in IBD. Enterobacteriaceae and other groups thriving in inflamed environments can dominate, perpetuating immune activation and contributing to symptoms.
Disrupted mucus layer and barrier function
The microbiome in IBD is often found closer to the gut lining than in healthy individuals, indicating the protective mucus layer is compromised. This allows bacteria to interact directly with immune cells in the gut wall, triggering or sustaining inflammation. The mucus layer, normally a buffer between microbes and tissue, becomes thinner and less effective.
How the microbiome differs in IBS
IBS is not inflammatory, and microbiome changes are generally subtler, more variable, and less consistent across individuals.
Modest shifts in diversity
Some people with IBS show mild reductions in microbial diversity, but many have profiles broadly similar to healthy individuals. Differences are less pronounced than in IBD and do not correlate strongly with symptom severity. There is no signature microbiome pattern for IBS as there often is in active IBD.
Variable changes in bacterial composition
Certain bacterial groups may be slightly altered in IBS, but findings differ widely between studies and individuals. Some research notes small increases in Firmicutes or reductions in Bifidobacterium, but patterns are inconsistent. Unlike IBD, there is no clear, reproducible loss of anti-inflammatory species or bloom of pro-inflammatory bacteria.
Functional changes rather than structural damage
In IBS, the microbiome may influence symptoms more through effects on gut motility, sensitivity, and metabolite production than through inflammatory pathways. Certain bacteria produce gases like hydrogen or methane contributing to bloating and discomfort. Others may alter gut transit time or nerve ending sensitivity. These are functional changes, not inflammatory or destructive ones.
Post-infectious changes
A subset develop IBS following gastroenteritis, known as post-infectious IBS. In these cases, microbiome changes may be more pronounced short-term, but the gut lining typically heals without ongoing inflammation. The microbiome may remain subtly altered, contributing to lingering changes in motility and sensation.
Why these differences matter clinically
Understanding microbiome differences clarifies why treatments for IBD and IBS differ. In IBD, the goal is reducing immune activation and inflammation, often using immunosuppressive medications, biologics, or dietary strategies modulating inflammatory pathways. Microbiome changes in IBD are closely tied to disease activity and immune dysfunction.
In IBS, the focus is symptom management through dietary changes, stress reduction, gut-targeted therapies, and sometimes specific probiotics or low-FODMAP diets. Because IBS involves no inflammation or tissue damage, immune suppression is inappropriate. Microbiome-focused interventions in IBS aim to reduce bloating, improve motility, or calm gut sensitivity rather than dampen immune responses.
Misdiagnosis can lead to ineffective or inappropriate treatment. Someone with undiagnosed IBD treated only for IBS may continue experiencing tissue damage and complications. Conversely, someone with IBS may undergo unnecessary testing or receive unneeded medications.
Practical takeaways
- If you have ongoing gut symptoms, seek a clear diagnosis. Endoscopy, imaging, and blood tests can distinguish IBD from IBS.
- Microbiome changes in IBD are usually more severe and linked to inflammation, while changes in IBS are subtler and more functional.
- Probiotic and dietary strategies differ between conditions. What helps in IBS may not address inflammation in IBD, and vice versa.
- In IBD, maintaining remission with appropriate medication and diet can help stabilise the microbiome over time.
- In IBS, working with a dietitian on tailored dietary approaches, such as low-FODMAP diet, may help reduce symptoms without addressing inflammation.
Conclusion
The microbiome behaves differently in IBD and IBS because the underlying biology differs fundamentally. In IBD, the microbiome reflects and contributes to ongoing immune activation and tissue damage, with reduced diversity and loss of protective bacteria. In IBS, microbiome changes are more variable and functional, influencing symptoms without causing inflammation. Recognising these differences is essential for accurate diagnosis, appropriate treatment, and informed long-term gut health management.
References
- Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. doi:10.1007/s12328-017-0813-5
- Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-16736. doi:10.1073/pnas.0804812105
- Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813-822. doi:10.1136/gutjnl-2016-313235
- Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome: a systematic review. Gastroenterology. 2019;157(1):97-108. doi:10.1053/j.gastro.2019.03.049
- Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8):497-505. doi:10.1038/nrgastro.2014.40
- Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. doi:10.1038/nmicrobiol.2017.4
- Duan R, Zhu S, Wang B, et al. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review. Clin Transl Gastroenterol. 2019;10(2):e00012. doi:10.14309/ctg.0000000000000012
- Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655-662. doi:10.1038/s41586-019-1237-9
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.